342 filings
Page 4 of 18
8-K
obpf38rvbc3h1q 8k
21 May 14
Other Events
12:00am
8-K
dpmekmxr5rhy nkl
7 May 14
ARIAD Reports First Quarter 2014 Financial Results and Development Progress
12:00am
8-K
ciw6rronxio
1 May 14
Departure of Directors or Certain Officers
12:00am
8-K
x74baj0 dmriokq7cuds
24 Mar 14
ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer
12:00am
8-K
uiko c18xf
25 Feb 14
ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014
12:00am
8-K
iecqv4xoakbp8 rak7q
21 Feb 14
Nomination and Standstill Agreement
12:00am
8-K
oykk8h7ln2isqd4zlj7u
5 Feb 14
Other Events
12:00am
8-K
4gb59460i4bgf
17 Jan 14
Other Events
12:00am
8-K
cudx9ovri3ea2
20 Dec 13
ARIAD Announces U.S. Resumption of Marketing and Commercial Distribution of Iclusig (ponatinib) in Refractory Philadelphia-Positive Leukemias
12:00am
8-K
iq4djzxg98m612zb
22 Nov 13
ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias
12:00am
8-K
vhhadn1mh4
12 Nov 13
ARIAD Reports Third Quarter 2013 Financial Results and Announces Significant Expense Reduction
12:00am
8-K/A
b7obvwk0s046w5iep
5 Nov 13
Entry into a Material Definitive Agreement
12:00am
8-K
mg45zql610
1 Nov 13
Entry into a Material Definitive Agreement
12:00am
8-K
vyrjqrxqztfvqpmrioi
31 Oct 13
ARIAD Announces Temporary Suspension of Iclusig Marketing in the United States
12:00am
8-K
cde29
18 Oct 13
ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
12:00am
8-K
2b8tei zy
9 Oct 13
ARIAD Announces Changes in the Clinical Development Program of Iclusig
12:00am
8-K
2g9mos9ydweim9jrmi
30 Sep 13
ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with Non-Small Cell Lung Cancer
12:00am
8-K
azqa4c1xa8njkyg8msf
18 Sep 13
Entry into a Material Definitive Agreement
12:00am
8-K
qrux 7hixdvixcct92yb
4 Sep 13
Interim Analysis of Efficacy in Newly Diagnosed Patients With Chronic Myeloid Leukemia Expected in Third Quarter of 2014
12:00am
8-K
072b5ih5fm0
7 Aug 13
ARIAD Reports Second Quarter 2013 Financial Results and Development Progress
12:00am